Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Michael Gnant, Amylou C. Dueck, Sophie Frantal, et al.
Journal of Clinical Oncology (2021) Vol. 40, Iss. 3, pp. 282-293
Open Access | Times Cited: 173

Showing 1-25 of 173 citing articles:

Ribociclib plus Endocrine Therapy in Early Breast Cancer
Dennis J. Slamon, O. N. Lipatov, Zbigniew Nowecki, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 12, pp. 1080-1091
Closed Access | Times Cited: 137
Recent advances in targeted strategies for triple-negative breast cancer
Shuangli Zhu, Yuze Wu, Bin Song, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 113
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
Laura Morrison, Sibylle Loibl, Nicholas C. Turner
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 2, pp. 89-105
Closed Access | Times Cited: 109
Systemic therapy for early-stage breast cancer: learning from the past to build the future
Elisa Agostinetto, Joseph Gligorov, Martine Piccart
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 12, pp. 763-774
Open Access | Times Cited: 84
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Priya Rastogi, Joyce O’Shaughnessy, Miguel Martín, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 9, pp. 987-993
Open Access | Times Cited: 80
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3
M.P. Goetz, M. Toi, Jens Huober, et al.
Annals of Oncology (2024) Vol. 35, Iss. 8, pp. 718-727
Open Access | Times Cited: 78
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022
Nina Ditsch, Achim Wöcke, Michael Untch, et al.
Breast Care (2022) Vol. 17, Iss. 4, pp. 403-420
Open Access | Times Cited: 72
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
Dennis J. Slamon, Peter A. Fasching, Sara A. Hurvitz, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 68
Breast cancer: pathogenesis and treatments
Xin Xiong, Lewei Zheng, Yu‐Qiang Ding, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 14
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Ilenia Pellarin, Alessandra Dall’Acqua, Andrea Favero, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping
Carsten Denkert, Sivaramakrishna Rachakonda, Thomas Karn, et al.
Cancer Cell (2025) Vol. 43, Iss. 2, pp. 232-247.e4
Open Access | Times Cited: 3
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant
Patrick Neven, PA Fasching, Stephen Chia, et al.
Breast Cancer Research (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 33
St. Gallen/Vienna 2023: Optimization of Treatment for Patients with Primary Breast Cancer – A Brief Summary of the Consensus Discussion
Marija Balić, Christoph Thomssen, Michael Gnant, et al.
Breast Care (2023) Vol. 18, Iss. 3, pp. 213-222
Open Access | Times Cited: 30
Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review
Subarnarekha Chatterji, Emma Krzoska, Christopher W Thoroughgood, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 2, pp. e74-e85
Open Access | Times Cited: 23
Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Georg Pfeiler, Dominik Hlauschek, Erica L. Mayer, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 33, pp. 5118-5130
Closed Access | Times Cited: 23
A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2− early breast cancer: final invasive disease–free survival results from the NATALEE trial
Gabriel N. Hortobágyi, Aleksandra Łacko, Joohyuk Sohn, et al.
Annals of Oncology (2024)
Closed Access | Times Cited: 11
CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms
Alyson Haslam, Sruthi Ranganathan, Vinay Prasad, et al.
European Journal of Cancer (2024) Vol. 207, pp. 114192-114192
Open Access | Times Cited: 8
Secreted LGALS3BP facilitates distant metastasis of breast cancer
Seung-Su Kim, Issac Park, Jeesoo Kim, et al.
Breast Cancer Research (2025) Vol. 27, Iss. 1
Open Access | Times Cited: 1
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer
Eva Valentina Klocker, Daniel Egle, Rupert Bartsch, et al.
Drugs (2025)
Open Access | Times Cited: 1
Final Survival Results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy – PENELOPE-B
S. Loibl, Miguel Martín, H. Bonnefoi, et al.
Annals of Oncology (2025)
Closed Access | Times Cited: 1
Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor–Positive Breast Cancer
Barbara Pistilli, Caroline Lohrisch, Jori Sheade, et al.
American Society of Clinical Oncology Educational Book (2022), Iss. 42, pp. 60-72
Closed Access | Times Cited: 37
Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review
Vincenzo Di Lauro, Giacomo Barchiesi, Federica Martorana, et al.
ESMO Open (2022) Vol. 7, Iss. 6, pp. 100629-100629
Open Access | Times Cited: 31
The impact of early palliative care on the quality of life of patients with advanced pancreatic cancer: The IMPERATIVE case-crossover study
Christina Kim, Stephanie Lelond, Paul Daeninck, et al.
Supportive Care in Cancer (2023) Vol. 31, Iss. 4
Open Access | Times Cited: 22
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer
Tomer Meirson, Daniel A. Goldstein, Bishal Gyawali, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 6, pp. 589-593
Closed Access | Times Cited: 17
Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2− breast cancer: an umbrella review
Dongqing Pu, Debo Xu, Yue Wu, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 1
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top